Catabasis Pharma (CATB) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Catabasis (CATB) PT Raised to $9 at H.C. Wainwright; Reiterates Buy
August 14, 2017 8:23 AM EDTH.C. Wainwright raised its price target on Catabasis (NASDAQ: CATB) to $9.00 (from $8.00) while maintaining a Buy rating.
The 24-week results from the open-label extension of the MoveDMD trial (Part C) is needed to finalize the Phase 3 trial plan. Analyst Carol Werther... More
